Market Overview

Amarin Receives Notification of Patent Allowance for 13/614,146 Related to Vascepa, FDA Approved MARINE Indication

Share:
Related AMRN
Benzinga's Top Initiations
Amarin Offers New Clinical, Pre-Clinical Data at ACC Meeting Related to Effect of EPA Therapy in Statin-Treated Patients
Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa (Seeking Alpha)

Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/614,146. This application includes claims intended to protect the Vascepa^® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. After issuance, Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

The claims in this allowed application cover a method of use relating to Vascepa's MARINE indication.  Specifically, the allowed independent claim covers use of icosapent ethyl, or EPA, including Vascepa, in lowering triglycerides through the daily administration of about 2500 mg to about 5000 mg of EPA, independent of DHA content, present in one or more capsules, effective to lower triglycerides in the subject by at least 25% without increasing LDL-C by more than 5%.

Posted-In: News

 

Related Articles (AMRN)

View Comments and Join the Discussion!